Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
A randomized phase II study of OGX-427 plus...
Conference

A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Abstract

121 Background: Heat Shock Protein 27 (Hsp27) is a stress-activated, multi-functional chaperone protein highly expressed in cancer that regulates cell signaling and survival pathways implicated in cancer progression. In prostate cancer models, Hsp27 complexes with androgen receptor (AR) and enhances transactivation of AR-regulated genes. OGX-427 is a 2nd generation antisense that inhibits Hsp27 expression with in vitro and in …

Authors

Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Kollmannsberger CK; Yu EY; Gleave ME

Volume

30

Pagination

pp. 121-121

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

February 10, 2012

DOI

10.1200/jco.2012.30.5_suppl.121

Conference proceedings

Journal of Clinical Oncology

Issue

5_suppl

ISSN

0732-183X